シスプラチン肝動脈化学塞栓療法時の悪心・嘔吐に対するグラニセトロン3日間投与とパロノセトロン1日間投与の後ろ向き比較試験
「緒言」肝動脈化学塞栓療法 (transcatheter arterial chemoembolization : TACE) は, 経カテーテル的に肝動脈内へ抗がん薬および塞栓物質を注入することで, 腫瘍部位における抗がん薬の濃度を高めるとともに, 腫瘍を阻血壊死に陥らせる治療法である. 進行肝細胞がんに対するTACEは, 複数のランダム化比較試験およびメタアナリシスにおいて無治療と比較して有意に生存を改善することが報告されており, 本邦の肝がん診療ガイドラインにおいて, 腫瘍個数4個以上, Child-Pugh分類のA～B, performance status (PS) 0のbarcel...
Saved in:
| Published in | 医療薬学 Vol. 45; no. 5; pp. 262 - 271 |
|---|---|
| Main Authors | , , , , , |
| Format | Journal Article |
| Language | Japanese |
| Published |
一般社団法人日本医療薬学会
10.05.2019
日本医療薬学会 |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | 「緒言」肝動脈化学塞栓療法 (transcatheter arterial chemoembolization : TACE) は, 経カテーテル的に肝動脈内へ抗がん薬および塞栓物質を注入することで, 腫瘍部位における抗がん薬の濃度を高めるとともに, 腫瘍を阻血壊死に陥らせる治療法である. 進行肝細胞がんに対するTACEは, 複数のランダム化比較試験およびメタアナリシスにおいて無治療と比較して有意に生存を改善することが報告されており, 本邦の肝がん診療ガイドラインにおいて, 腫瘍個数4個以上, Child-Pugh分類のA～B, performance status (PS) 0のbarcelona clinic liver cancer (BCLC) stage B (intermediate stage) の手術不能でかつ穿刺局所療法の対象とならない多血性肝細胞がんに対する治療法として強く推奨されている. |
|---|---|
| AbstractList | 「緒言」肝動脈化学塞栓療法 (transcatheter arterial chemoembolization : TACE) は, 経カテーテル的に肝動脈内へ抗がん薬および塞栓物質を注入することで, 腫瘍部位における抗がん薬の濃度を高めるとともに, 腫瘍を阻血壊死に陥らせる治療法である. 進行肝細胞がんに対するTACEは, 複数のランダム化比較試験およびメタアナリシスにおいて無治療と比較して有意に生存を改善することが報告されており, 本邦の肝がん診療ガイドラインにおいて, 腫瘍個数4個以上, Child-Pugh分類のA～B, performance status (PS) 0のbarcelona clinic liver cancer (BCLC) stage B (intermediate stage) の手術不能でかつ穿刺局所療法の対象とならない多血性肝細胞がんに対する治療法として強く推奨されている. |
| Author | 大橋, 崇志 三島, 八重子 齊藤, 妙子 新井, 隆広 藤田, 行代志 野川, 秀之 |
| Author_xml | – sequence: 1 fullname: 新井, 隆広 organization: 群馬県立がんセンター薬剤部 – sequence: 2 fullname: 藤田, 行代志 organization: 群馬県立がんセンター薬剤部 – sequence: 3 fullname: 大橋, 崇志 organization: 群馬県立がんセンター薬剤部 – sequence: 4 fullname: 齊藤, 妙子 organization: 群馬県立がんセンター薬剤部 – sequence: 5 fullname: 野川, 秀之 organization: 群馬県立がんセンター消化器内科 – sequence: 6 fullname: 三島, 八重子 organization: 群馬県立がんセンター薬剤部 |
| BookMark | eNpVkctqFEEUhguJYIxZ-hg91rW7eqcEjULAjYK7orqn23Qz0zN0x4XLrnIRzIUJk0mchaILQ6LkAlmoROLDlNVO3sLKREE35xz4__P9cM5NMFP0igSA2wi2mE_DO3neX46rFmUt7ONrYBZxjj1Ew3DGzYT6HqH42Q0wX1VZBCELIUbMnwUnRn0x6pvRu0YfGF0bfTpRb-3aaPJq1a7v2MM9--Fd8374a6ya01EzVqY-atQn-0MbfWbfbNvBwNSf7fG5qcdGrRl1MuW44czoVaMPHZA0ux8vdobN69HPr5um3jd6ayps_mtC_5uO7Pm6URt2sGXqjeZ4e_JdTw72LvaHt8D1VHaqZP5PnwNPH9x_svDQW3q8-Gjh3pKXE4ShR5I05BJDRAhhKPCTMApSP4kJDwiMofR52g6IzyPKeCqjgKYcIswwiXnoFEzmwOIVt5u0s1h2ekUnKxKR916UhcsV7Yj1l2XZFS4jFBBSBplrREB3f1cCRHBAAwYd6e4VKa9W5PNE9MusK8uXQpYrWdxxyOnnBGWCXZbL9b9S7BJELslvC-jQQg |
| ContentType | Journal Article |
| Copyright | 2019 日本医療薬学会 |
| Copyright_xml | – notice: 2019 日本医療薬学会 |
| CorporateAuthor | 群馬県立がんセンター薬剤部 群馬県立がんセンター消化器内科 |
| CorporateAuthor_xml | – name: 群馬県立がんセンター薬剤部 – name: 群馬県立がんセンター消化器内科 |
| DOI | 10.5649/jjphcs.45.262 |
| DatabaseTitleList | |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1882-1499 |
| EndPage | 271 |
| ExternalDocumentID | db5pharm_2019_004505_003_0262_02713274750 article_jjphcs_45_5_45_262_article_char_ja |
| GroupedDBID | .LE 5GY ALMA_UNASSIGNED_HOLDINGS KQ8 MOJWN RJT ABJNI |
| ID | FETCH-LOGICAL-j3120-3ef98a2013335176e9b7f6ec38730c0a68fd7368b458fab74f8012523c89fd723 |
| ISSN | 1346-342X |
| IngestDate | Fri Nov 08 06:51:04 EST 2024 Wed Apr 05 04:37:26 EDT 2023 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | false |
| IsScholarly | true |
| Issue | 5 |
| Language | Japanese |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-j3120-3ef98a2013335176e9b7f6ec38730c0a68fd7368b458fab74f8012523c89fd723 |
| OpenAccessLink | https://www.jstage.jst.go.jp/article/jjphcs/45/5/45_262/_article/-char/ja |
| PageCount | 10 |
| ParticipantIDs | medicalonline_journals_db5pharm_2019_004505_003_0262_02713274750 jstage_primary_article_jjphcs_45_5_45_262_article_char_ja |
| PublicationCentury | 2000 |
| PublicationDate | 20190510 |
| PublicationDateYYYYMMDD | 2019-05-10 |
| PublicationDate_xml | – month: 05 year: 2019 text: 20190510 day: 10 |
| PublicationDecade | 2010 |
| PublicationTitle | 医療薬学 |
| PublicationTitleAlternate | 医療薬学 |
| PublicationYear | 2019 |
| Publisher | 一般社団法人日本医療薬学会 日本医療薬学会 |
| Publisher_xml | – name: 一般社団法人日本医療薬学会 – name: 日本医療薬学会 |
| References | 32）Peng JW, Lin GN, Xiao JJ, Jiang XM, Hepatitis B virus reactivation in hepatocellular carcinoma patients undergoing transcatheter arterial chemoembolization therapy, Asia Pac J Clin Oncol, 2012, 8, 356-361. 9）Takayasu K, Muramatsu Y, Maeda T, Iwata R, Furukawa H, Muramatsu Y, Moriyama N, Okusaka T, Okada S, Ueno H, Targeted transarterial oily chemoembolization for small foci of hepatocellular carcinoma using a unified helical CT and angiography system: analysis of factors affecting local recurrence and survival rates, AJR Am J Roentgenol, 2001, 176, 681-688. 18）Tanaka J, Koyama T, Mizui M, Uchida S, Katayama K, Matsuo J, Akita T, Nakashima A, Miyakawa Y, Yoshizawa H, Total numbers of undiagnosed carriers of hepatitis C and B viruses in Japan estimated by age- and area-specific prevalence on the national scale, Intervirology, 2011, 54, 185-195. 39）Shimizu H, Suzuki K, Uchikura T, Tsuji D, Yamanaka T, Hashimoto H, Goto K, Matsui R, Seki N, Shimada T, Ikeda S, Ikegami N, Hama T, Yamamoto N, Sasaki T, Economic analysis of palonosetron versus granisetron in the standard triplet regimen for preventing chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy in Japan (TRIPLE phase III trial), J Pharm Health Care Sci, 2018, 4, 31. doi:10.1186/s40780-018-0128-9. 16）Ito Y, Tsuda T, Minatogawa H, Kano S, Sakamaki K, Ando M, Tsugawa K, Kojima Y, Furuya N, Matsuzaki K, Fukuda M, Sugae S, Ohta I, Arioka H, Tokuda Y, Narui K, Tsuboya A, Suda T, Morita S, Boku N, Yamanaka T, Nakajima TE, Placebo-Controlled, Double-Blinded Phase III Study Comparing Dexamethasone on Day 1 With Dexamethasone on Days 1 to 3 With Combined Neurokinin-1 Receptor Antagonist and Palonosetron in High-Emetogenic Chemotherapy, J Clin Oncol, 2018, 36, 1000-1006. 10）Kasugai H, Kojima J, Tatsuta M, Okuda S, Sasaki Y, Imaoka S, Fujita M, Ishiguro S, Treatment of hepatocellular carcinoma by transcatheter arterial embolization combined with intraarterial infusion of a mixture of cisplatin and ethiodized oil, Gastroenterology, 1989, 97, 965-971. 6）Kawai S, Tani M, Okamura J, Ogawa M, Ohashi Y, Monden M, Hayashi S, Inoue J, Kawarada Y, Kusano M, Prospective and randomized clinical trial for the treatment of hepatocellular carcinoma- a comparison between L-TAE with farmorubicin and L-TAE with adriamycin : preliminary results (second cooperative study). Cooperative Study Group for Liver Cancer Treatment of Japan, Cancer Chemother Pharmacol, 1994, 33, 97-102. 29）Schmoll HJ, Aapro MS, Poli-Bigelli S, Kim HK, Park K, Jordan K, von Pawel J, Giezek H, Ahmed T, Chan CY, Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment, Ann Oncol, 2006, 17, 1000-1006. 36）Prior A, Read NW, Reduction of rectal sensitivity and post-prandial motility by granisetron, a 5 HT3-receptor antagonist, in patients with irritable bowel syndrome, Aliment Pharmacol Ther, 1993, 7, 175-180. 14）Uyama N, Hatano E, Maetani Y, Isoda H, Shibata T, Taura K, Oe S, Naito M, Yasuchika K, Fujii H, Ikai I, Uemoto S, Efficacy and toxicity of transcatheter arterial chemoembolization with cisplatin suspended in lipiodol for unresectable hepatocellular carcinoma, Gan To Kagaku Ryoho, 2008, 35, 775-780. 22）Liu Q, Ma A, Shen J, Effects of ondansetron, granisetron, and tropisetron on vomiting caused by transcatheter arterial chemoembolization (TACE), J Pharm Pract, 2008. http://en.cnki.com.cn/Article_en/CJFDTotal-YXSJ200801016.htm, 2018 Nov 31. 2）Llovet JM, Real MI, Montaña X, Planas R, Coll S, Aponte J, Ayuso C, Sala M, Muchart J, Solà R, Rodés J, Bruix J, Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial, Lancet, 2002, 359, 1734-1739. 15）De Leon A, Palonosetron (Aloxi): a second-generation 5-HT3 receptor antagonist for chemotherapy-induced nausea and vomiting, Proc (Bayl Univ Med Cent), 2006, 19, 413-416. 1）Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, Fan ST, Wong J, Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma, Hepatology, 2002, 35, 1164-1171. 30）Suzuki K, Yamanaka T, Hashimoto H, Shimada Y, Arata K, Matsui R, Goto K, Takiguchi T, Ohyanagi F, Kogure Y, Nogami N, Nakao M, Takeda K, Azuma K, Nagase S, Hayashi T, Fujiwara K, Shimada T, Seki N, Yamamoto N, Randomized, double-blind, phase III trial of palonosetron versus granisetron in the triplet regimen for preventing chemotherapy-induced nausea and vomiting after highly emetogenic chemotherapy: TRIPLE study, Ann Oncol, 2016, 27, 1601-1606. 40）Valery PC, Laversanne M, Clark PJ, Petrick JL, McGlynn KA, Bray F, Projections of primary liver cancer to 2030 in 30 countries worldwide, Hepatology, 2018, 67, 600-611. 19）日本肝癌研究会, 第19回全国原発性肝癌追跡調査報告（2006～2007）, 日本肝癌研究会, 大阪, 2016, pp45-73. 23）仁尾祐太, 北原加奈之, 鈴木康介, 岡﨑敬之介, 齋藤 勲, 下間 祐, 魚住祥二郎, 伊藤敬義, 村山純一郎, 肝細胞癌に対する肝動脈化学塞栓療法施行時の抗菌薬および制吐療法の有効性, 昭和学士会誌, 2015, 75, 337-342. 4）日本肝臓学会編, “科学的根拠に基づく肝癌診療ガイドライン”, 2017年版, 金原出版, 東京, 2017, pp157-160. 28）Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, Julie Ma G, Eldridge K, Hipple A, Evans JK, Horgan KJ, Lawson F, Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America, Cancer, 2003, 97, 3090-3098. 25）Popovic M, Warr DG, Deangelis C, Tsao M, Chan KK, Poon M, Yip C, Pulenzas N, Lam H, Zhang L, Chow E, Efficacy and safety of palonosetron for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis of randomized controlled trials, Support Care Cancer, 2014, 22, 1685-1697. 13）Iwasa S, Ikeda M, Okusaka T, Ueno H, Morizane C, Nakachi K, Mitsunaga S, Kondo S, Hagihara A, Shimizu S, Satake M, Arai Y, Transcatheter arterial infusion chemotherapy with a fine-powder formulation of cisplatin for advanced hepatocellular carcinoma refractory to transcatheter arterial chemoembolization, Jpn J Clin Oncol, 2011, 41, 770-775. 34）Molassiotis A, Lee PH, Burke TA, Dicato M, Gascon P, Roila F, Aapro M, Anticipatory Nausea, Risk Factors, and Its Impact on Chemotherapy-Induced Nausea and Vomiting: Results From the Pan European Emesis Registry Study, J Pain Symptom Manage, 2016, 51, 987-993. 5）Nishimine K, Uchida H, Matsuo N, Sakaguchi H, Hirohashi S, Nishimura Y, Guo Q, Ohishi H, Nagano N, Yoshioka T, Segmental transarterial chemoembolization with Lipiodol mixed with anticancer drugs for nonresectable hepatocellular carcinoma: follow-up CT and therapeutic results, Cancer Chemother Pharmacol, 1994, 33, 60-68. 17）Komatsu Y, Okita K, Yuki S, Furuhata T, Fukushima H, Masuko H, Kawamoto Y, Isobe H, Miyagishima T, Sasaki K, Nakamura M, Ohsaki Y, Nakajima J, Tateyama M, Eto K, Minami S, Yokoyama R, Iwanaga I, Shibuya H, Kudo M, Oba K, Takahashi Y, Open-label, randomized, comparative, phase III study on effects of reducing steroid use in combination with Palonosetron, Cancer Sci, 2015, 106, 891-895. 8）Sasaki Y, Imaoka S, Kasugai H, Fujita M, Kawamoto S, Ishiguro S, Kojima J, Ishikawa O, Ohigashi H, Furukawa H, A new approach to chemoembolization therapy for hepatoma using ethiodized oil, cisplatin, and gelatin sponge, Cancer, 1987, 60, 1194-1203. 24）Bernardo G, Palumbo R, Frascaroli M, Bernardo A, Losurdo A, Poggi G, Teragni C, Albanese D, Amatu A, Strada MR, Palonosetron compared to ondansetron in the prevention of chemotherapy-induced nausea and vomiting: Activity, safety and cost-effectiveness evaluation, J Clin Oncol, 2009, 27 (suppl), e20573. doi: 10.1200/jco.2009.27.15_suppl.e20573. 26）SY, Clark-Snow RA, Danso MA, Dennis K, Dupuis LL, Dusetzina SB, Eng C, Feyer PC, Jordan K, Noonan K, Sparacio D, Somerfield MR, Lyman GH, Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update, J Clin Oncol, 2017, 35, 3240-3261. 33）Saito B, Nakashima H, Abe M, Murai S, Baba Y, Arai N, Kawaguchi Y, Fujiwara S, Kabasawa N, Tsukamoto H, Uto Y, Ariizumi H, Yanagisawa K, Hattori N, Harada H, Nakamaki T, Efficacy of palonosetron to prevent delayed nausea and vomiting in non-Hodgkin’s lymphoma patients undergoing repeated cycles of the CHOP regimen, Support Care Cancer, 2018, 26, 269-274. 38）山西由里子, 田隝博樹, 池田俊也, 山田治美, 井上忠夫, 武田弘志, がん化学療法における5-HT3受容体拮抗剤“パロノセトロン静注”の薬剤経済学的検討, 日本緩和医療薬学, 2014, 7, 37-43. 12）Kasugai H, Kojima J, Tatsuta H, Okuda S, Sasaki Y, Imaoka S, Fujita M, Ishiguro S, Treatment of hepatocellular carcinoma by transcatheter arterial embolization combined with intraarterial infusion of a mixture of cisplatin and ethiodized oil, Gastroenterology, 1989, 97, 965-971. 37）Kabuki M, Higashihara H, Kakuda M, Fujita Y, Masuda J, Kin K, Ueguchi T, Osuga K, Tomiyama N, Impact of preventive administration of antiemetic drugs on risk of acute nausea and vomiting induced by transcatheter arterial chemoembolization in patients with hepatocellular carcinomas - A retrospective study, Jpn J Cancer Chemother, 2013, 40, 197-201. 27）Hesketh PJ, Grunberg SM, Gralla RJ, Warr DG, Roila F, de Wit R, Chawla SP, Carides AD, Ianus J, Elmer ME, Evans JK, Beck K, Reines S, Horgan KJ, The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin－the Aprepitant Protocol 052 Study Group, J Clin Oncol, 2003, 21, 4112-4119. 21）Schwartzberg L, Barbour SY, Morrow GR, Ballinari G, Thorn MD, Cox D, Pooled analysis of phase III clinical studies of palonosetron versus ondansetron, dolasetron, and granisetron in the prevention of chemotherapy-induced nausea and vomiting (CINV), Support Care Cancer, 2014, 22, 469-477. 11）日本癌治療学会編, “制吐薬適正使用ガイドライン”, 第2版, 金原出版, 東京, 2015, pp24-46. 7）Bronowicki JP, Vetter D, Dumas F, Boudjema K, Bader R, Weiss AM, Wenger JJ, Boisse P, Bigard MA, Doffoel M, Tran |
| References_xml | |
| SSID | ssib005902156 ssib003116159 ssib002484604 ssib000871962 ssib023157658 ssj0069027 |
| Score | 2.1989222 |
| Snippet | 「緒言」肝動脈化学塞栓療法 (transcatheter arterial chemoembolization : TACE) は, 経カテーテル的に肝動脈内へ抗がん薬および塞栓物質を注入することで, 腫瘍部位における抗がん薬の濃度を高めるとともに, 腫瘍を阻血壊死に陥らせる治療法である.... |
| SourceID | medicalonline jstage |
| SourceType | Publisher |
| StartPage | 262 |
| SubjectTerms | antiemetic therapy cisplatin dexamethasone nausea and vomiting palonosetron transcatheter arterial chemoembolization |
| Title | シスプラチン肝動脈化学塞栓療法時の悪心・嘔吐に対するグラニセトロン3日間投与とパロノセトロン1日間投与の後ろ向き比較試験 |
| URI | https://www.jstage.jst.go.jp/article/jjphcs/45/5/45_262/_article/-char/ja http://mol.medicalonline.jp/library/journal/download?GoodsID=db5pharm/2019/004505/003&name=0262-0271j |
| Volume | 45 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| ispartofPNX | 医療薬学, 2019/05/10, Vol.45(5), pp.262-271 |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpR3LitRAMMh6EUR84ps52J6cdTLdnXTf7MxkEUVRWGFvYTI7gwyoi7se9DaJB_HFyrrqHhQ9KD7wAR5UFP0Cv6LNuP6FVZ3OTFYFX5dQU13VXY9OuiqTrnacPa1ap0bZdKcqWlxWmYA7XVA3rsaQxUF4z_m0OSXiyFHv4Al2aIpPrRr7XPpq6dxcPN6-8Mt9Jf_iVcCBX3GX7F94dtgpIAAG_8IVPAzXP_IxCSkRdRL4BSANQIn0LaAKjHAtEFASCiSWTRJyIgIiucFAUCkMpkGkh4BqEpUDLpEhCT2iakQCu0-kxB4AA70hu1dgzEDKEMNPpZA9mMBx7egBYqQgkhkAP7MouEyTmiBBaDFSWr1ASKtg7Se9hk1BgREFTXOoMjUi-kSBrBLVkwYjlJGekQD0L0ZVBb90f-zI0vxmMPdvBguNhUK0utW1WRjGtTSI8dAwaDNBgoYxp0AboH8kSpyf_1hkGdaNKOXQVwIlUY2hY4s7zQjrGcuCaLmMILUiwvgeMIKOaIVRjJl-mWESOD1QeobjKWo9Lv0RE0cO5RstpPEYkMB0839BK0nQRFONRuKoJU4FI3h-6mvxngq3xmGJ2-GTpWR6ABpW4d_ZwggP016VlmjKvCpl9anyGp6XJLXPKl5ekO1an8d29fy4nx_DBu4xrLrb682cbM-OMz4-5FpRiX065jNYTz5C9SJMhmoca-tGNaCHi-9SfMeDbxBX12HdwwX38PFytuPDeleq1udiulWqnicxAB9mB5B5cd8bHX7gQbM5K6owQF4yGIXfv0J0CKZ7kFpizZC1p_K_e_OyO6XIeXK9s86mvBWVP782OKt6rY3O3mN5zfzz-yqToy2gs_sqeyvHRtX0z29yXunkjU7e6fS2Tp_otK_T18vJ3ezK4vLFS9nVW9nzR9mDe4P7C1-XksHrxcFSovsvBsnT7FOq0_fZnZvZ_LzuP8teftT9JZ1c0ckr0w8A73V6SafPoUM6uP3w262FweXFL2-v6_5jnd4wDdfLRO5KohfZx6s6uZbN39D9a4OXN5c_pMtPHn17vLDZOTERTjYOVu0xM9UedbF-RKcrRQt8Sinlru91ZOx3vU6bCoh-2rWWJ7rTPvVEzLjotmKfdTGq53XaFhJa6nSLM3b6zOnOVqfShuiG12UL6BiToiNY3G238Y0xTBXBWtscmXsmmslrCUV27YhyB0aMRxwvOKGKJtx-G_WA98AKZ0Z2IZqN_nhebv__LnY4a0Y3905nbO7suc4uSMvm4t1msn8HZ_lWyQ |
| link.rule.ids | 315,783,787,27936,27937 |
| linkProvider | Colorado Alliance of Research Libraries |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=%E3%82%B7%E3%82%B9%E3%83%97%E3%83%A9%E3%83%81%E3%83%B3%E8%82%9D%E5%8B%95%E8%84%88%E5%8C%96%E5%AD%A6%E5%A1%9E%E6%A0%93%E7%99%82%E6%B3%95%E6%99%82%E3%81%AE%E6%82%AA%E5%BF%83%E3%83%BB%E5%98%94%E5%90%90%E3%81%AB%E5%AF%BE%E3%81%99%E3%82%8B%E3%82%B0%E3%83%A9%E3%83%8B%E3%82%BB%E3%83%88%E3%83%AD%E3%83%B33%E6%97%A5%E9%96%93%E6%8A%95%E4%B8%8E%E3%81%A8%E3%83%91%E3%83%AD%E3%83%8E%E3%82%BB%E3%83%88%E3%83%AD%E3%83%B31%E6%97%A5%E9%96%93%E6%8A%95%E4%B8%8E%E3%81%AE%E5%BE%8C%E3%82%8D%E5%90%91%E3%81%8D%E6%AF%94%E8%BC%83%E8%A9%A6%E9%A8%93&rft.jtitle=%E5%8C%BB%E7%99%82%E8%96%AC%E5%AD%A6&rft.au=%E6%96%B0%E4%BA%95%E9%9A%86%E5%BA%83&rft.au=%E8%97%A4%E7%94%B0%E8%A1%8C%E4%BB%A3%E5%BF%97&rft.au=%E5%A4%A7%E6%A9%8B%E5%B4%87%E5%BF%97&rft.au=%E9%BD%8A%E8%97%A4%E5%A6%99%E5%AD%90&rft.date=2019-05-10&rft.pub=%E6%97%A5%E6%9C%AC%E5%8C%BB%E7%99%82%E8%96%AC%E5%AD%A6%E4%BC%9A&rft.issn=1346-342X&rft.volume=45&rft.issue=5&rft.spage=262&rft.epage=271&rft_id=info:doi/10.5649%2Fjjphcs.45.262&rft.externalDocID=db5pharm_2019_004505_003_0262_02713274750 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1346-342X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1346-342X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1346-342X&client=summon |